Human Genomics entered a new era with the completion in 2000 of the Human Genome Sequence Project.

Previously, gene mapping utilised non-coding markers for haplotype identification of gene regions of interest by linkage disequilibrium (LD) association (GTG U.S. Patent No. 5,851,762).  

Reservations have arisen about the resolving power of LD Mapping, in view of the different modes of inheritance of disease-associated genes, where two or more disease-contributory genes occur within a single Haplotypic block etc.  As a specific example, application of the non-coding Genomic patent to Nasopharyngeal carcinoma, using STRs for genome-wide association analysis, failed to detect the chromosome 6 HLA-associated risk which is best known to exist from affected sibling Haplotype sharing.  Yet this risk is extremely strong, with a lower relative risk bound of 20+ and an upper bound of infinity. 

In other words, application of non-coding based inference of risk gene regions had insufficient resolving power to detect one of the strongest genetic associations with a common human cancer.  (Ref. Feng et al. Nat Genet. 2002 Aug;31(4):395-9.)

A new paradigm for genome-wide gene search is required.  Simons Haplomics' Intellectual Property approach to this goal exploits the burgeoning coding region data that is emerging post-2000.

[ Home ] [ Up ]